News & Updates

Show Multimedia Only

Pivotal phase III trial shows Tx potential of oral carbapenem for cUTI or acute pyelonephritis

20 Nov 2025 by

Results from the phase III PIVOT-PO study demonstrate the potential of tebipenem pivoxil hydrobromide (TBP-PI) as an effective oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTI).

Pivotal phase III trial shows Tx potential of oral carbapenem for cUTI or acute pyelonephritis

20 Nov 2025

Kidney stone history linked to poor survival outcomes in upper tract urothelial carcinoma

18 Nov 2025

Among patients with upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy, those with a history of urinary tract stones appear to have poorer cancer-specific survival (CSS) and disease-free survival (DFS), according to a study.

Kidney stone history linked to poor survival outcomes in upper tract urothelial carcinoma

18 Nov 2025

AI model predicts prostate cancer

10 Nov 2025

An artificial intelligence (AI) model using diffusion basis spectrum imaging (DBSI) can accurately predict clinically significant prostate cancer (csPCa) on biopsy and even reduce unnecessary prostate biopsies when combined with Prostate Imaging Reporting and Data System (PI-RADS), suggests a study.

AI model predicts prostate cancer

10 Nov 2025

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

09 Nov 2025 by

In the frontline treatment of patients with HER2-expressing locally advanced or metastatic urothelial cancer, the combination of disitamab vedotin plus toripalimab yields a clinically meaningful and significant increase in survival compared with chemotherapy, as shown in the phase III RC48-C016 trial.

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

09 Nov 2025

Shift work a risk factor for kidney stones

04 Nov 2025 by

A recent study suggests a positive association between shift work and risk of kidney stone events, with lifestyle factors partially mediating the association.

Shift work a risk factor for kidney stones

04 Nov 2025

Extended PLND tied to improved survival in bladder cancer

03 Nov 2025

In patients with bladder cancer, extended pelvic lymph node dissection (PLND) is associated with favourable recurrence-free survival and 5-year recurrence rates, a study has shown.

Extended PLND tied to improved survival in bladder cancer

03 Nov 2025

Original New Drug Application Approvals by US FDA (16-30 September 2025)

31 Oct 2025

New drug applications approved by US FDA as of 16-30 September 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 September 2025)

31 Oct 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-September-2025

31 Oct 2025

New drug applications approved by US FDA as of 1-15 September 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.